According to a recent Ipsos poll commissioned by Tetra Bio-Pharma, it seems that Canadians believe that Doctor Knows Best when it comes to recommending cannabis for a medical ailment, even though they are less convinced that they are well enough informed to treat them with it.
Tetra Natural Heath announces that Hemp Energy Drink cans are now available in 59 grocery stores and convenience stores in British Columbia, Alberta, and Saskatchewan.
Tetra Bio-Pharma Inc. today announced accelerated development of its second-generation drug inhalation program for fibromyalgia and uncontrolled pain over the last months.
Tetra Bio-Pharma Inc. announces today that it has granted, pursuant to the Company's stock option plan (the "Plan"), 375,000 options to officers of the Company. Each option entitles its holder to purchase one common share of the Company.
Tetra Bio-Pharma Inc. today announced a change in their Drug Development Plan (DDP) priorities. This will allow Tetra to rapidly leverage the PANAG pipeline and expertise and align its research programs on indications with unmet medical needs or a higher return on investment (ROI).
Tetra Bio-Pharma Inc. today announced that it has temporarily suspended its phase 3 clinical program due to impurities found in its PPP001 investigational drug being administered to patients.
Crescita Therapeutics Inc. and Tetra Natural Health today announced an agreement to develop an enhanced version of Tetra’s dermatology portfolio using Crescita’s patented transdermal delivery technologies: Multiplexed Molecular Penetration Enhancer ("MMPE™") and DuraPeel™.
Tetra Bio-Pharma Inc. today announced it has entered into a definitive agreement with the shareholders (the "Vendors") of Panag Pharma Inc. for the previously-announced acquisition by Tetra of all of the issued and outstanding shares in the capital of Panag.
Tetra Bio-Pharma Inc. has announced that it filed a patent application for its PPP001 drug product. Tetra’s research has led to a significant discovery that has enabled the company to apply for patent protection.
Tetra Bio-Pharma Inc. today announced that its Phase 1 clinical trial in healthy volunteers using vaporized PPP001 has been successfully concluded. This trial was aimed at determining the pharmacokinetics (PK) and safety of a 4-day titration followed by a single dose of vaporized PPP001 in 12 healthy volunteers.